ZB012 for IgG4-Related Disease

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
IgG4-Related DiseaseObexelimab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD)

Eligible Conditions
  • IgG4-Related Disease

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Randomization to Week 52

Randomization to Week 52
measure

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

ZB012
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

200 Total Participants · 2 Treatment Groups

Primary Treatment: ZB012 · Has Placebo Group · Phase 3

ZB012
Drug
Experimental Group · 1 Intervention: Obexelimab · Intervention Types: Drug
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: randomization to week 52

Who is running the clinical trial?

Zenas BioPharma (USA), LLCLead Sponsor
2 Previous Clinical Trials
64 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patients must demonstrate active manifestations of IgG4-RD that necessitate the commencement or intensification of GC therapy.
You are at least 18 years old, regardless of gender.
You must meet the current ACR/EULAR standards for diagnosis of IgG4-RD.